Free Trial

Altamira Therapeutics (CYTO) Competitors

$1.48
-0.01 (-0.67%)
(As of 05/21/2024 ET)

CYTO vs. ATXI, DRMA, SLRX, SNOA, CMND, CNSP, NTBL, ONCO, GLMD, and SXTP

Should you be buying Altamira Therapeutics stock or one of its competitors? The main competitors of Altamira Therapeutics include Avenue Therapeutics (ATXI), Dermata Therapeutics (DRMA), Salarius Pharmaceuticals (SLRX), Sonoma Pharmaceuticals (SNOA), Clearmind Medicine (CMND), CNS Pharmaceuticals (CNSP), Notable Labs (NTBL), Onconetix (ONCO), Galmed Pharmaceuticals (GLMD), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical preparations" industry.

Altamira Therapeutics vs.

Altamira Therapeutics (NASDAQ:CYTO) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Avenue Therapeutics received 147 more outperform votes than Altamira Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Altamira TherapeuticsN/AN/A
Avenue TherapeuticsOutperform Votes
147
60.25%
Underperform Votes
97
39.75%

Company Net Margins Return on Equity Return on Assets
Altamira TherapeuticsN/A N/A N/A
Avenue Therapeutics N/A N/A -391.98%

1.9% of Altamira Therapeutics shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 13.0% of Altamira Therapeutics shares are held by insiders. Comparatively, 1.8% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Altamira Therapeutics has higher revenue and earnings than Avenue Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Altamira Therapeutics$320K7.31-$4.31MN/AN/A
Avenue TherapeuticsN/AN/A-$10.38M-$7.88-0.49

Altamira Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Altamira Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Avenue Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Avenue Therapeutics had 4 more articles in the media than Altamira Therapeutics. MarketBeat recorded 4 mentions for Avenue Therapeutics and 0 mentions for Altamira Therapeutics. Avenue Therapeutics' average media sentiment score of 0.04 beat Altamira Therapeutics' score of 0.00 indicating that Avenue Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Altamira Therapeutics Neutral
Avenue Therapeutics Neutral

Summary

Altamira Therapeutics and Avenue Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTO vs. The Competition

MetricAltamira TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.34M$6.88B$5.03B$7.99B
Dividend YieldN/A2.73%44.98%3.91%
P/E RatioN/A11.33128.5015.30
Price / Sales7.31267.442,527.4477.99
Price / CashN/A20.5132.6829.27
Price / Book0.325.965.014.46
Net Income-$4.31M$143.44M$103.71M$213.05M
7 Day Performance2.78%0.95%0.88%0.91%
1 Month Performance4.67%5.36%5.51%6.20%
1 Year Performance-91.64%-4.81%7.74%9.92%

Altamira Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATXI
Avenue Therapeutics
0.7399 of 5 stars
$3.84
-2.8%
N/A-95.2%$2.27MN/A-0.043Gap Down
DRMA
Dermata Therapeutics
0 of 5 stars
$0.34
-10.6%
N/A-90.1%$2.24MN/A-0.098Stock Split
Positive News
Gap Down
Trading Halted
SLRX
Salarius Pharmaceuticals
0 of 5 stars
$0.46
-6.2%
N/A-65.0%$2.34M$1.84M-0.102Positive News
Gap Down
SNOA
Sonoma Pharmaceuticals
2.2854 of 5 stars
$0.15
flat
$3.25
+2,045.2%
-76.1%$2.36M$12.31M-0.169Positive News
Gap Down
CMND
Clearmind Medicine
0 of 5 stars
$1.29
flat
N/A-93.5%$2.18MN/A0.00N/A
CNSP
CNS Pharmaceuticals
0 of 5 stars
$0.21
flat
N/A-86.4%$2.17MN/A-0.043Gap Up
NTBL
Notable Labs
2.9734 of 5 stars
$1.10
-7.6%
$8.00
+627.3%
N/A$2.44M$310,000.00-0.3013Gap Down
ONCO
Onconetix
0 of 5 stars
$0.11
flat
N/AN/A$2.48M$60,000.00-0.1012News Coverage
Gap Down
GLMD
Galmed Pharmaceuticals
0 of 5 stars
$0.40
+5.2%
N/A-92.0%$2.04MN/A-0.123Analyst Forecast
Gap Down
SXTP
60 Degrees Pharmaceuticals
2.3062 of 5 stars
$0.22
flat
$2.40
+998.4%
N/A$2.53M$250,000.000.003Analyst Revision
News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:CYTO) was last updated on 5/21/2024 by MarketBeat.com Staff

From Our Partners